Court Approves Vermillion Reorganization; Firm Raises $43M | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion said after the close of the market Thursday that the US Bankruptcy Court for the District of Delaware has approved the firm's plan of reorganization.

Gail Page, executive chairperson of the firm's board of directors, said that the firm, in collaboration with its partner, Quest Diagnostics, is now poised to commercialize Vermillion's OVA1 ovarian tumor triage diagnostic test. "Additionally, we will be able to continue the development of the other potential tests in our pipeline," Page said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.

Sequencing is enabling the roots of some rare diseases to be determined, the Financial Times reports.

Proove Biosciences had allegedly been paying doctors to perform its opioid risk and other genetic tests, Stat News reports.

A floated budget plan could see non-military discretionary spending in the US — which includes science agency funding — fall, the New York Times reports.